Ehsan Malek

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9440699/publications.pdf

Version: 2024-02-01

85 papers	2,084 citations	393982 19 h-index	253896 43 g-index
85 all docs	85 docs citations	85 times ranked	3314 citing authors

#	Article	IF	Citations
1	Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia, 2019, 33, 2266-2275.	3.3	385
2	Novel therapies emerging in oncology to target the TGF-Î² pathway. Journal of Hematology and Oncology, 2021, 14, 55.	6.9	192
3	Correlation of long non-coding RNA expression with metastasis, drug resistance and clinical outcome in cancer. Oncotarget, 2014, 5, 8027-8038.	0.8	177
4	Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet Haematology,the, 2019, 6, e459-e469.	2.2	174
5	NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 11-20.	2.3	142
6	NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1154-1165.	2.3	113
7	Myeloid-derived suppressor cells: The green light for myeloma immune escape. Blood Reviews, 2016, 30, 341-348.	2.8	105
8	Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib. Leukemia, 2015, 29, 2184-2191.	3.3	88
9	Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma. Oncotarget, 2015, 6, 3098-3110.	0.8	69
10	Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. Cancer, 2020, 126, 5077-5087.	2.0	47
11	Significance of the absolute lymphocyte/monocyte ratio as a prognostic immune biomarker in newly diagnosed multiple myeloma. Blood Cancer Journal, 2017, 7, e579-e579.	2.8	40
12	MicroRNAs in Brain Metastases: Potential Role as Diagnostics and Therapeutics. International Journal of Molecular Sciences, 2014, 15, 10508-10526.	1.8	37
13	Pomalidomide plus lowâ€dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure. British Journal of Haematology, 2020, 188, 501-510.	1.2	36
14	Metabolic tumor volume on interim PET is a better predictor of outcome in diffuse large B-cell lymphoma than semiquantitative methods. Blood Cancer Journal, 2015, 5, e326-e326.	2.8	34
15	Gastrointestinal Microbiome and Mycobiome Changes during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot Study. Biology of Blood and Marrow Transplantation, 2019, 25, 1511-1519.	2.0	33
16	Bortezomib induces AMPK-dependent autophagosome formation uncoupled from apoptosis in drug resistant cells. Oncotarget, 2014, 5, 12358-12370.	0.8	31
17	A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia. Clinical Cancer Research, 2019, 25, 4231-4237.	3.2	30
18	Interference of Therapeutic Monoclonal Antibodies With Routine Serum Protein Electrophoresis and Immunofixation in Patients With Myeloma. American Journal of Clinical Pathology, 2018, 150, 121-129.	0.4	28

#	Article	IF	Citations
19	Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 326-335.	0.2	27
20	Overall survival of patients with tripleâ€class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in <scp>MAMMOTH</scp>. American Journal of Hematology, 2021, 96, E5-E8.	2.0	20
21	A Phase I Study of Ixazomib in Combination with Panobinostat and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma. Blood, 2015, 126, 4221-4221.	0.6	19
22	Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies. Leukemia, 2022, 36, 877-880.	3.3	18
23	Identification of Long Nonâ€Coding RNAs Deregulated in Multiple Myeloma Cells Resistant to Proteasome Inhibitors. Genes, 2016, 7, 84.	1.0	15
24	Nivolumab before and after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2017, 52, 1054-1056.	1.3	15
25	African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. Cancer, 2021, 127, 82-92.	2.0	15
26	Socioeconomic Factors and Survival of Multiple Myeloma Patients. Cancers, 2021, 13, 590.	1.7	14
27	Allograft for Myeloma: Examining Pieces of the Jigsaw Puzzle. Frontiers in Oncology, 2017, 7, 287.	1.3	12
28	Low dose anti-thymocyte globulin reduces chronic graft-versus-host disease incidence rates after matched unrelated donor transplantation. Leukemia and Lymphoma, 2018, 59, 1644-1651.	0.6	11
29	Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. Biology of Blood and Marrow Transplantation, 2018, 24, 2443-2449.	2.0	11
30	Impact of lenalidomide on collected hematopoietic myeloid and erythroid progenitors: peripheral stem cell collection may not be affected. Leukemia and Lymphoma, 2019, 60, 2199-2206.	0.6	10
31	Subsequent Treatment Outcomes of Multiple Myeloma Refractory to CD38-Monoclonal Antibody Therapy. Blood, 2018, 132, 2015-2015.	0.6	10
32	Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined Analysis of the STORM and Mammoth Studies. Blood, 2019, 134, 3125-3125.	0.6	10
33	Immune Signatures Associated With Clonal Isotype Switch After Autologous Stem Cell Transplantation for Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e213-e220.	0.2	9
34	Aggressive lymphoma subtype is a risk factor for venous thrombosis. Development of lymphoma â€• specific venous thrombosis prediction models. American Journal of Hematology, 2020, 95, 918-926.	2.0	8
35	DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. Seminars in Hematology, 2021, 58, 45-55.	1.8	8
36	Racial and age-related disparities in early mortality affect the outcomes of multiple myeloma patients. Leukemia, 2021, 35, 250-254.	3.3	8

#	Article	IF	Citations
37	Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma. Leukemia and Lymphoma, 2018, 59, 1905-1912.	0.6	7
38	Natural History of Patients with Multiple Myeloma Refractory to CD38-Targeted Monoclonal Antibody-Based Treatment. Blood, 2018, 132, 3233-3233.	0.6	6
39	Continuous Temperature Monitoring for Earlier Fever Detection in Neutropenic Patients: Patient's Acceptance and Comparison with Standard of Care. Biology of Blood and Marrow Transplantation, 2018, 24, S108-S109.	2.0	5
40	Identifying Neutropenic Fever Earlier: An Application of a Skin Patch for Continuous Temperature Monitoring. Blood, 2018, 132, 4718-4718.	0.6	5
41	Serum electrolyte dynamics in multiple myeloma patients undergoing autologous haematopoietic stem cell transplantation. Nephrology, 2020, 25, 450-456.	0.7	4
42	Preclinical Studies and a Phase I Trial of the TGF-Î² Receptor Inhibitor, Vactosertib (TEW-7197), in Combination with Pomalidomide in Patients with Multiple Myeloma Refractory to Bortezomib or Lenalidomide. Blood, 2018, 132, 1962-1962.	0.6	4
43	Vactosertib, a TGF-ÃŸ Receptor I Kinase/ALK5 Inhibitor, Diminishes Tumor Progression and Bone Disease in a Mouse Model of Multiple Myeloma and Overcomes Resistance to Proteasome Inhibitors. Blood, 2018, 132, 1918-1918.	0.6	4
44	Preclinical Studies and Phase I Trial of Vactosertib in Combination with Pomalidomide in Relapsed Multiple Myeloma: A Corticosteroid-Free Approach By Targeting TGF-Î² Signaling Pathway. Blood, 2019, 134, 3232-3232.	0.6	4
45	Cardiovascular Toxicity after Therapy for Diffuse Large B Cell Lymphoma Occurs Early and Results in Decreased Overall Survival.. Blood, 2016, 128, 105-105.	0.6	4
46	High throughput chemical library screening identifies a novel p110-Î´ inhibitor that potentiates the anti-myeloma effect of bortezomib. Oncotarget, 2016, 7, 38523-38538.	0.8	4
47	FDG PET imaging in multiple myeloma: implications for response assessments in clinical trials. American Journal of Nuclear Medicine and Molecular Imaging, 2018, 8, 421-427.	1.0	4
48	Predicting Successful Phase Advancement and Regulatory Approval in Multiple Myeloma From Phase I Overall Response Rates. JCO Clinical Cancer Informatics, 2017, 1, 1-14.	1.0	3
49	Timing Embryo Preservation for a Patient with High-Risk Newly Diagnosed Acute Myeloid Leukemia. Case Reports in Hematology, 2018, 2018, 1-3.	0.3	3
50	Reducing Gastrointestinal Toxicity Associated with Autologous Transplantation for Multiple Myeloma without Compromising Its Anti-Myeloma Effect. Blood, 2017, 130, 680-680.	0.6	3
51	Real world vs. clinical trial outcomes of triple class refractory penta-exposed multiple myeloma (MM). Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e115-e116.	0.2	2
52	Efficacy and cost-benefit of filgrastim administered after early assessment bone marrow biopsy during induction therapy for acute myeloid leukemia. Leukemia and Lymphoma, 2021, 62, 1450-1457.	0.6	2
53	Pomalidomide + Low-Dose Dexamethasone Following Second-Line Lenalidomide-Based Therapy in Relapsed or Refractory Multiple Myeloma: A Phase 2 Study Investigating Efficacy and Safety. Blood, 2016, 128, 4497-4497.	0.6	2
54	Inotuzumab Ozogamicin Post-Transplant for Acute Lymphocytic Leukemia. Blood, 2019, 134, 1948-1948.	0.6	2

#	Article	IF	Citations
55	Risk Model to Predict Supraventricular Arrhythmias in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant. Biology of Blood and Marrow Transplantation, 2019, 25, S156-S157.	2.0	1
56	Dynamics of Serum Electrolyte Changes at the Peri-Engraftment Period in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant. Biology of Blood and Marrow Transplantation, 2019, 25, S138-S140.	2.0	1
57	Risk of Progression Across Age and Race for Patients with Smoldering Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e325.	0.2	1
58	Comparison of Peripheral Blast Clearance and Day 14 Bone Marrow Biopsy in Predicting Remission Status and Survival After 7+3 Induction in Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 73-82.	0.2	1
59	Host and Disease Factors Impacting Presence of Accessory Band during Therapy with Daratumumab in Multiple Myeloma Patients. Biology of Blood and Marrow Transplantation, 2020, 26, S390.	2.0	1
60	Significant costs and low utilization of stored peripheral blood stem cells for salvage autologous transplant in multiple myeloma patients including those meeting mSMART criteria. Bone Marrow Transplantation, 2021, 56, 1458-1461.	1.3	1
61	Natural History of Patients with Multiple Myeloma Refractory to Elotuzumab and Outcomes of Subsequent Therapy with Anti-CD38 Monoclonal Antibodies. Blood, 2018, 132, 3303-3303.	0.6	1
62	Patterns of Care of Diffuse Large B Cell Lymphoma Patients 80 Years and Older: Worse Outcomes after Treatment without Increased Relapse. Blood, 2018, 132, 575-575.	0.6	1
63	Low Dose Antithymocyte Globulin (ATG) for Graft-Versus-Host Disease (GVHD) Prophylaxis. Blood, 2016, 128, 5788-5788.	0.6	1
64	Pharmacogenomics of Bortezomib in Multiple Myeloma Patients Reveals That the Ubiquitin Ligase SCF-Skp2 Promotes Drug Resistance. Blood, 2015, 126, 3021-3021.	0.6	1
65	Immunologic Status Evaluated By the Absolute Lymphocyte/Monocyte Ratio Provides a Powerful Prognostic Tool for Newly Diagnosed Multiple Myeloma. Blood, 2016, 128, 1862-1862.	0.6	1
66	Comparison of Pegfilgrastim and Filgrastim to Prevent Neutropenic Fever during Consolidation with High Dose Cytarabine for Acute Myeloid Leukemia. Blood, 2018, 132, 1404-1404.	0.6	1
67	Stem Cell Transplant Minimizes Insurance Coverage-Driven Outcomes Disparities for Multiple Myeloma Patients. Blood, 2019, 134, 424-424.	0.6	1
68	Post-Transplant Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia. Blood, 2021, 138, 2899-2899.	0.6	1
69	Low Dose Daily Corticosteroid Tapering Regimen Allows Highly Effective and Practical Desensitization for Multiple Myeloma Patients with Skin Rash after Immunomodulatory Drugs. Blood, 2020, 136, 19-20.	0.6	1
70	Resistant or Sensitive: Time is of the Essence. Biology of Blood and Marrow Transplantation, 2016, 22, 1907-1908.	2.0	0
71	Early Versus Late Initiation of Granulocyte Colony Stimulating Factor (G-CSF) Following Autologous Hematopoietic Stem Cell Transplantation in Adult Hematological Malignancies. Biology of Blood and Marrow Transplantation, 2018, 24, S138-S139.	2.0	0
72	Venous Thromboembolic Events in Diffuse Large B Cell Lymphoma Patients: Risk Factors and Outcomes. Blood, 2016, 128, 3611-3611.	0.6	0

#	Article	IF	Citations
73	A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/ Refractory Acute Myeloid Leukemia (AML). Blood, 2016, 128, 4065-4065.	0.6	0
74	Rethinking Risk-Benefit Assessment for Phase I Multiple Myeloma Trials. Blood, 2016, 128, 1146-1146.	0.6	0
75	Venous thromboembolism (VTE) in multiple myeloma (MM) patients undergoing autologous hematopoietic cell transplantation (HCT).. Journal of Clinical Oncology, 2017, 35, e19503-e19503.	0.8	0
76	Impact of Maintenance Therapy on Nature of First Relapse in Multiple Myeloma Patients Underwent Autologous Stem Cell Transplant. Blood, 2018, 132, 2130-2130.	0.6	0
77	Relative Abundance Analysis of the Oral and Gastrointestinal Microbiome during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot Study and Association with Transplant Outcomes. Blood, 2018, 132, 5754-5754.	0.6	0
78	Presence of Chip-Mutated Autologous Hematopoietic Cells in Mobilized Peripheral Blood Products Is Associated with Shorter Progression-Free Survival after Autologous Transplants for Multiple Myeloma. Blood, 2019, 134, 515-515.	0.6	0
79	A highly effective and practical desensitization regimen: Results in comparable clinical outcomes for multiple myeloma patients with skin rash after immunomodulatory drugs.. Journal of Clinical Oncology, 2020, 38, 12104-12104.	0.8	0
80	A phase II, single-arm study of denosumab in multiple myeloma patients with renal insufficiency.. Journal of Clinical Oncology, 2020, 38, 8520-8520.	0.8	0
81	Epigenetic Priming with Pre-Transplant Oral Panobinostat Followed By Post-Transplant Consolidation. Blood, 2021, 138, 2917-2917.	0.6	0
82	Mycobiome Supporting Diet to Reduce Gastrointestinal (GI)Toxicity Associated with Autologous Stem Cell Transplant (ASCT) for Patients with Multiple Myeloma (MM). Blood, 2021, 138, 3948-3948.	0.6	0
83	Health Care Burden of Monogammopathy of Renal Significance. Blood, 2020, 136, 34-36.	0.6	0
84	Development of a Machine Learning Algorithm for Rapid, Point-of-Care Prediction of Serum Monoclonal Proteins in Multiple Myeloma. Blood, 2020, 136, 13-15.	0.6	0
85	Patient Selection Bias Limits the Real World Efficacy of Randomized Clinical Trials in Multiple Myeloma. Blood, 2020, 136, 1-2.	0.6	0